- The Final Safety and Performance Based Pathway Guidance Is Out February 21, 2019
- Balancing Benefit and Risk in Medical Device Regulation February 20, 2019
- CBER’s Learnings on Regenerative Medicine Development Reflected in Guidance Updates February 19, 2019
- You Down With CGT? February 18, 2019
- FDA Announces Various Initiatives to Increase Oversight of the Dietary Supplement Industry February 15, 2019
- Big Molecule Watch Blog
- Bloomberg BNA Health Care Blog
- Drug and Device Law Blog
- Eye on FDA
- FDA Matters
- Harvard Law Bill of Health
- IN VIVO Blog
- Internet Drug News.com
- Lachman Consultants Blog
- Medical Devices Today
- Orange Book Blog
- Patent Baristas
- Patent Docs
- Pharma IQ
- Pharmalot
- SCOTUS Blog
- The Volokh Conspiracy
- WLF Legal Pulse
- Advertising and Promotion (Federal Trade Commission)
- Advertising and Promotion (OPDP)
- Animal Drugs and Feeds
- Biosimilars
- Cannabis
- cGMP Compliance
- Consumer Product Safety Commission
- Controlled Substances
- Cosmetics
- Current Affairs
- Dietary Supplements
- Drug Development
- Drug Enforcement Administration
- Enforcement
- FDA News
- Foods
- Foods and Dietary Supplements
- Fraud and Abuse
- Government Pricing
- Hatch-Waxman
- Health Care
- Health Privacy
- Import/Export
- In Vitro Diagnostic Devices
- Jobs
- Medical Devices
- Miscellaneous
- Orphan Drugs
- OTC Drugs and Cosmetics
- Prescription Drugs and Biologics
- Product Jurisdiction and Combination Products
- Reimbursement
- Tissue Products
- Tobacco
- Uncategorized
President Obama to Nominate Maureen K. Ohlhausen to the Federal Trade Commission
July 20, 2011By Kurt R. Karst —By Kurt R. Karst –
On July 19th, President Obama announced his intent to nominate Maureen K. Ohlhausen as a Commissioner of the Federal Trade Commission (“FTC”). Ms. Ohlhausen is currently a partner at Wilkinson Barker Knauer LLP, where she specializes in privacy, data protection, and cybersecurity. Ms. Ohlhausen previously worked at the FTC from 1997 to 2008. From 2004 to 2008, she served as Director of the Office of Policy Planning, where she supervised the development of reports, amicus briefs, and advocacy filings on competition and consumer protection topics, principally focusing on e-commerce, advertising, and technology issues. Additional background information is available here.
If confirmed by the Senate, Ms. Ohlhausen would serve a 7-year term on the 5-member board, which currently includes Commissioners Jon Leibowitz, J. Thomas Rosch, William E. Kovacic, Edith Ramirez, and Julie Brill. Ms. Ohlhausen would be replacing William E. Kovacic, whose term expires in September.
Search FDA Law Blog
Subscribe
Enter your email address to automatically receive new posts to the FDA Law Blog via e-mail.
Latest Tweets
Tweets by @fdalawblogAwards & Honors
- The Best
Lawyers in America
US News & World Report - Ranked in Chambers USA 2018
- The Final Safety and Performance Based Pathway Guidance Is Out February 21, 2019
- Balancing Benefit and Risk in Medical Device Regulation February 20, 2019
- CBER’s Learnings on Regenerative Medicine Development Reflected in Guidance Updates February 19, 2019
- You Down With CGT? February 18, 2019
- FDA Announces Various Initiatives to Increase Oversight of the Dietary Supplement Industry February 15, 2019
- Big Molecule Watch Blog
- Bloomberg BNA Health Care Blog
- Drug and Device Law Blog
- Eye on FDA
- FDA Matters
- Harvard Law Bill of Health
- IN VIVO Blog
- Internet Drug News.com
- Lachman Consultants Blog
- Medical Devices Today
- Orange Book Blog
- Patent Baristas
- Patent Docs
- Pharma IQ
- Pharmalot
- SCOTUS Blog
- The Volokh Conspiracy
- WLF Legal Pulse
- Advertising and Promotion (Federal Trade Commission)
- Advertising and Promotion (OPDP)
- Animal Drugs and Feeds
- Biosimilars
- Cannabis
- cGMP Compliance
- Consumer Product Safety Commission
- Controlled Substances
- Cosmetics
- Current Affairs
- Dietary Supplements
- Drug Development
- Drug Enforcement Administration
- Enforcement
- FDA News
- Foods
- Foods and Dietary Supplements
- Fraud and Abuse
- Government Pricing
- Hatch-Waxman
- Health Care
- Health Privacy
- Import/Export
- In Vitro Diagnostic Devices
- Jobs
- Medical Devices
- Miscellaneous
- Orphan Drugs
- OTC Drugs and Cosmetics
- Prescription Drugs and Biologics
- Product Jurisdiction and Combination Products
- Reimbursement
- Tissue Products
- Tobacco
- Uncategorized